The updated Global Plan calls for 2.6 billion USD per year for vital research and development of new TB diagnostic tools, new drug regimens and a new vaccine, and 13 billion USD per year for TB care and prevention.
Geneva/Jakarta. 10 December 2019 - The Stop TB Partnership today launched the updated Global Plan to End TB 2018-2022, which calls for 2.6 billion USD per year for vital research and development of new tuberculosis (TB) diagnostic tools, new drug regimens and a new vaccine, and 13 billion USD per year for TB care and prevention.
If the updated Global Plan is fully funded and implemented, countries will reach UNHLM on TB treatment targets set for 2022, including putting 40 million people on treatment for TB, including 3.5 million children and 1.5 million people with drug-resistant TB. This will lead to 1.5 million fewer deaths due to TB, and the return on investment will be 44 USD for 1 USD spent. On the other hand, a five-year delay in increasing funding for TB research and development would lead to approximately 2 million more people dying and an additional 13.9 million people developing TB.
"The coming three years, up to 2022, will be important for the TB Community at large. This is when we make it or break it. The good news is that we have what is needed to make it, including country targets as shares of the UNHLM TB targets. As incoming chairperson of the Stop TB Board, I will do my best to have this plan implemented, executed & funded." Dr Luiz Mandetta, Brazil Minister of Health and Chairperson of the Stop TB Partnership Board.
Source: Stop TB Partnership